Share：
Share this content in WeChat
X
[Chinese][PDF]6721
• Clinical Article •
Feasibility study of three-dimensional amide proton transfer imaging in differentiating prostate cancer with and without bone metastasis
ZHANG Pengyun  TANG Yunxing  JIANG Haoyang  CHEN Lihua  ZHANG Qinhe  LIN Liangjie  LIU Ailian 

Cite this article as: Zhang PY, Tang YX, Jiang HY, et al. Feasibility study of three-dimensional amide proton transfer imaging in differentiating prostate cancer with and without bone metastasis[J]. Chin J Magn Reson Imaging, 2022, 13(12): 100-103, 110. DOI:10.12015/issn.1674-8034.2022.12.017.


[Abstract] Objective The study aims to explore the performance of 3D amide proton transfer (3D-APT) weighted imaging in differentiation of prostate cancer (PCa) with and without bone metastasis.Materials and Methods A total of 62 (from April 2019 to August 2022) pathology-proven PCa patient cases were included categorized into two groups: 21 PCas with bone metastasis, and 41 without bone metastasis. Bone metastasis was proved by emission computed tomography (ECT). MR scans were performed on a 3.0 T clinical scanner with the body coil to transmit RF pulse and a 16-channel abdominal coil to receive signals. MR sequences including 3D-APT, T2 weighted imaging (T2WI), and diffusion weighted imaging (DWI) were performed. All data were transferred to the IntelliSpace Portal workstation and processed independently by two observers using a double-blind method. According to T2WI and DWI images, the lesions were identified. On the 3D-APT and DWI fusion images, the circular region of interest (ROI) was manually delineated to measure the APT value. The mean APT values from the ROIs were used for statistical analysis by the SPSS 19.0 software (IBM). Measurement consistency of APT values between the two observers was tested using intra-class correlation coefficients (ICC). APT values were compared between twogroups using the t test. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy.Results Measurements by the two observers were in good agreement (ICC＞0.75). APT values in group PCa with bone metastasis (2.76%±0.44%) were significantly higher than those in group PCa without bone metastasis (2.26%±0.64%) (P＜0.05). The area under the ROC curves (AUC) of APT for distinguishing the lesions between two groups was 0.766. The diagnostic sensitivity and specificity were 71.43% and 70.73%, respectively, with the cut-off APT value of 2.50%.Conclusions In this study, 3D-APT imaging technology was used for the first time to distinguish PCa with and without bone metastasis, PCas with bone metastases were observed with significantly higher mean APT values than those without bone metastasis. The diagnostic sensitivity and specificity of APT imaging for differentiation of these two type PCas were good. Therefore, APT imaging may serve as a promising non-invasive method for clinical evaluation of the aggressiveness of PCa.
[Keywords] prostate cancer；bone metastasis；amide proton transfer weighted imaging；magnetic resonance imaging；emission computed tomography；diffusion weighted imaging

ZHANG Pengyun1   TANG Yunxing1   JIANG Haoyang1   CHEN Lihua1   ZHANG Qinhe1   LIN Liangjie2   LIU Ailian1*  

1 Department of Radiology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

2 Philips (China) Investment Co., LTD, Beijing Branch, Beijing 100016, China

Liu AL, E-mail: liuailian@dmu.edu.cn

Conflicts of interest   None.

Received  2022-02-24
Accepted  2022-11-29
DOI: 10.12015/issn.1674-8034.2022.12.017
Cite this article as: Zhang PY, Tang YX, Jiang HY, et al. Feasibility study of three-dimensional amide proton transfer imaging in differentiating prostate cancer with and without bone metastasis[J]. Chin J Magn Reson Imaging, 2022, 13(12): 100-103, 110. DOI:10.12015/issn.1674-8034.2022.12.017.

[1]
Wang SC, Ting WC, Chang YC, et al. Whole pelvic radiotherapy with stereotactic body radiotherapy boost vs. conventionally fractionated radiotherapy for patients with high or very high-risk prostate cancer[J/OL]. Front Oncol, 2020, 10: 814 [2022-10-23]. https://www.frontiersin.org/articles/10.3389/fonc.2020.00814. DOI: 10.3389/fonc.2020.00814.
[2]
Fang YQ, Zhou XF. Interpretation of the update points of the 2020 edition of the guidelines for diagnosis and treatment of prostate cancer of European Urology Society[J/OL]. Chinese Journal of Endoscopic Urology (electronic edition), 2020, 14 (6): 401-404 [2022-11-02]. http://qikan.cqvip.com/Qikan/Article/Detail?id=7103633127. DOI: 10.3877/cma.j.issn.1674-3253.2020.06.001.
[3]
Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease[J]. J Urol, 2002, 168(3): 1008-1012. DOI: 10.1097/01.ju.0000026656.62692.67.
[4]
Manfredi M, Mele F, Garrou D, et al. Multiparametric prostate MRI: technical conduct, standardized report and clinical use[J]. Italian J Urol Nephrol, 2018, 70(1): 9-21. DOI: 10.23736/S0393-2249.17.02846-6.
[5]
Tabotta F, Jreige M, Schaefer N, et al. Quantitative bone SPECT/CT: high specificity for identification of prostatecancer bone metastases[J/OL]. BMC Musculoskel Dis, 2019, 20(1): 619-625 [2022-11-02]. https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-019-3001-6. DOI: 10.1186/s12891-019-3001-6.
[6]
Zacho HD, Ravn S, Afshar-Oromieh A, et al. Added value of 68 Ga-PSMA PET/CT for the detection of bone metastases inpatients with newly diagnosed prostate cancer and a previous99mTc bone scintigraphy[J/OL]. EJNMMI Res, 2020, 10(1): 31-39 [2022-11-02]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-00618-0. DOI: 10.1186/s13550-020-00618-0.
[7]
Kamimura K, Nakajo M, Yoneyama T, et al. Amide proton transfer imaging of tumors: theory, clinical applications, pitfalls, and future directions[J]. Jpn J Radiol, 2019, 37(2): 109-116. DOI: 10.1007/s11604-018-0787-3.
[8]
Zhou CY, Chen JZ, He JW, et al. Imaging analysis of bone metastases in the extremities[J]. J Pract Radiol, 2013, 29(11): 1823-1825, 1843. DOI: 10.3969/j.issn.1002-1671.2013.11.027.
[9]
Nishie A, Takayama Y, Asayama Y, et al. Amide proton transfer imaging can predict tumor grade in rectal cancer[J]. Magn Reson Imaging, 2018, 51: 96-103. DOI: 10.1016/j.mri.2018.04.017.
[10]
Msayib Y, Harston GWJ, Tee YK, et al. Quantitative CEST imaging of amide proton transfer in acute ischaemic stroke[J/OL]. Neuroimage Clin, 2019, 23: 101833 [2022-11-02]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411782. DOI: 10.1016/j.nicl.2019.101833.
[11]
Li S, Chan P, Li C, et al. Changes of Amide Proton Transfer Imaging in Multiple System Atrophy Parkinsonism Type[J/OL]. Front Aging Neurosci, 2020, 12: 572421 [2022-11-02]. https://www.frontiersin.org/articles/10.3389/fnagi.2020.572421. DOI: 10.3389/fnagi.2020.572421.
[12]
Deng J, Zhan RS, Wang WG. Research progress of prostate cancer bone metastasis[J]. J Clin Res, 2020(3): 325-328. DOI: 10.3969/j.issn.1671-7171.2020.03.002.
[13]
Yin H, Wang D, Yan R, et al. Comparison of Diffusion Kurtosis Imaging and Amide Proton Transfer Imaging in the Diagnosis and Risk Assessment of Prostate Cancer[J/OL]. Front Oncol, 2021, 11: 640906 [2022-11-02]. https://www.frontiersin.org/articles/10.3389/fonc.2021.640906.
[14]
Yin HJ, Han DM, Zhai ZS, et al. Diagnosis of amide proton transfer imaging between prostatic cancer and benign prostatic hyperplasia[J]. Chin J Med Imaging, 2019, 27(12): 938-941. DOI: 10.3969/j.issn.1005-5185.2019.12.014.
[15]
Li X, Zeng XY. Advances in epidemiology of prostate cancer in China[J]. Cancer Res Prev Treat, 2021, 48(1): 98-102. DOI: 10.3971/j.issn.1000-8578.2021.20.0370.
[16]
Ji HL, Wang M, Miao P, et al. Progress in treatment of advanced prostate cancer[J]. Lab Med Clin, 2020, 17(20): 3041-3044. DOI: 10.3969/j.issn.1672-9455.2020.20.041.
[17]
Sun Y, Reynolds HM, Parameswaran B, et al. Multiparametric MRI and radiomics in prostate cancer: a review[J]. Australas Phys Eng Sci Med, 2019, 42(1): 3-25. DOI: 10.1007/s13246-019-00730-z.
[18]
Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST)[J]. J Magn Reson, 2000, 143(1): 79-87. DOI: 10.1006/jmre.1999.1956.
[19]
Jia X, Lai C, Ma XH. Progress in clinical research of amide proton transfer imaging[J]. Chinese Journal of Medical Instrumentation, 2020, 44(2): 185-188. DOI: 10.3969/j.issn.1671-7104.2020.02.018.
[20]
Milot L. Amide proton transfer-weighted MRI: insight into cancer cell biology[J]. Radiology, 2022, 305(1): 135-136. DOI: 10.1148/radiol.221376.
[21]
Joo B, Han K, Choi YS, et al. Amide proton transfer imaging for differentiation of benign and atypical meningiomas[J]. Eur Radiol, 2018, 28(1): 331-339. DOI: 10.1007/s00330-017-4962-1.
[22]
Bai Y, Lin YS, Zhang W, et al. Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas[J]. Oncotarget, 2017, 8(4): 5834-5842. DOI: 10.18632/oncotarget.13970.
[23]
By S, Barry RL, Smith AK, et al. Amide proton transfer CEST of the cervical spinal cord in multiple sclerosis patients at 3T[J]. Magn Reson Med, 2018, 79(2): 806-814. DOI: 10.1002/mrm.26736.
[24]
Zöllner HJ, Butz M, Jördens M, et al. Chemical exchange saturation transfer imaging in hepatic encephalopathy[J/OL]. Neuroimage Clin, 2019, 22: 101743 [2022-11-02]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411782. DOI: 10.1016/j.nicl.2019.101743.
[25]
He YL, Li Y, Lin CY, et al. Three-dimensional turbo-spin-echo amide proton transfer-weighted MRI for cervical cancer: a preliminary study[J]. J Magn Reson Imaging, 2019, 50(4): 1318-1325. DOI: 10.1002/jmri.26710.
[26]
Jia G, Abaza R, Williams JD, et al. Amide proton transfer MR imaging of prostate cancer: a preliminary study[J]. J Magn Reson Imaging, 2011, 33(3): 647-654. DOI: 10.1002/jmri.22480.
[27]
Takayama Y, Nishie A, Sugimoto M, et al. Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: comparison with Gleason scores[J]. MAGMA, 2016, 29(4): 671-679. DOI: 10.1007/s10334-016-0537-4.
[28]
Dou WQ, Lin CE, Ding HY, et al. Chemical exchange saturation transfer magnetic resonance imaging and its main and potential applications in pre-clinical and clinical studies[J]. Quant Imaging Med Surg, 2019, 9(10): 1747-1766. DOI: 10.21037/qims.2019.10.03.
[29]
Togao O, Yoshiura T, Keupp J, et al. Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades[J]. Neuro Oncol, 2013, 16(3): 441-448. DOI: 10.1093/neuonc/not158.

PREV Preoperative contrast-enhanced MRI based on radiomics analysis to predict the recurrence of hepatocellular carcinoma after resection
NEXT Application of MRI apparent diffusion coefficient in identifying prognostic risk stratification of prostate cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn